Allergy Therapeutics PLC Key paper published in the World Allergy Journal
August 10 2015 - 2:00AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
10 August 2015
10 August 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Key paper on proteomics in the field of allergy published in the
World Allergy Journal
Allergy Therapeutics, the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, today
announces the publication of a key paper(1) and featured article in
the World Allergy Journal about proteomics in the field of
allergy.
Dr Murray Skinner, Chief Scientific Officer, has led a team of
scientists at Allergy Therapeutics to use a novel proteomic
approach to understand the molecular fingerprint underpinning the
causative agents of leading causes of allergy.
Using a variety of complimentary analytical techniques, lead
author Dr Matthew Heath, Senior Scientist and Principal Medical
Writer has identified new functional and evolutionary relationships
between allergens across species such as grasses and trees to
further understand the specifics of patient sensitisation. This
study is aligned with European Medicine Agency guidelines
consistent with assessment of complex allergen mixes to support
advanced new regulatory requirements.
Dr Murray Skinner, Chief Scientific Officer at Allergy Therapeutics, said:
"Our development of proteomic and allergomic concepts as
described in this paper underpins our track record in the
scientific advancement of our product portfolio, which is an
important part of our growth strategy, These advancements reinforce
our focus on patient care and our commitment to invest both in
existing and future products to ensure patients receive the
treatment they deserve".
1 - M D Heath et al., Molecular, proteomic and immunological
parameters of allergens provide inclusion criteria for new
candidates within established grass and tree homologous groups.
World Allergy Organization Journal 2015, 8:21
- Ends -
For further information:
+44 (0) 1903 845
Allergy Therapeutics 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
+44 (0) 20 7886
Panmure Gordon 2500
Freddy Crossley / Peter Steel / Duncan Monteith,
Corporate Finance
Tom Salvesen, Corporate Broking
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway / Victoria Foster Mitchell
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company
focused on allergy vaccination. It has a growing business achieving
revenue in the last financial year of GBP42 million mainly in
Europe through its own sales and marketing infrastructure and
further afield through distributors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUAGRUPAGQM
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024